Grace Therapeutics CFO Robert DelAversano Receives 33,660 Share Award

What Happened
Robert J. DelAversano, Principal Financial Officer of Grace Therapeutics (GRCE), was granted 33,660 derivative shares (award/option) on 2026-08-28. The grant price is $0.00 (no cash paid). This is an equity award as part of compensation, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-28; Form 4 filed 2026-09-01 (timely within required business days).
• Amount: 33,660 derivative shares/options granted at $0.00.
• Vesting: grant vests quarterly in substantially equal installments over 3 years. The first 1/12 vests immediately; the remaining 11/12 vest equally over the next 11 quarters, subject to continuous service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction type: Award/Grant (code A); not an open-market buy or sale.

Context
This is a routine equity compensation grant to an executive; such grants are common for retention and incentive purposes and do not by themselves indicate buying or selling sentiment. Because these are derivative awards with multi-quarter vesting, their economic benefit to the insider depends on continued service and future stock performance.